Business

How This Business Actually Works

Centene is a government-rate spread business: it collects mostly fixed premiums and wins only when medical claims plus administration leave a sliver of underwriting margin. What matters most is not revenue growth, but whether Medicaid rates, Marketplace risk adjustment, Medicare bids, and provider contracts keep pace with member morbidity. The market is most likely overestimating how quickly scale fixes mispriced risk, and underestimating how valuable even 100 bps of HBR improvement would be on a $174.6B premium-and-service revenue base.

The revenue engine is simple; the operating reality is not. Centene receives per-member premiums from states, CMS, and subsidized Marketplace customers, then pays providers, pharmacies, and care vendors. The bottleneck is actuarial truth arriving late: claims data, acuity shifts, provider billing behavior, risk adjustment, and state rate cycles all move after enrollment decisions have already been made.

The visual point is that Centene has enormous revenue and almost no room for error. Medicaid is the center of gravity, but Commercial/Marketplace caused the sharper 2025 profit break because risk-adjustment and morbidity assumptions changed faster than pricing.

Centene's bargaining power is real but conditional. States and CMS need large, compliant plans with local networks, but they also recapture excess economics through rate reviews, minimum MLRs, risk corridors, procurement rebids, and quality requirements. Providers need the member volume, yet network adequacy rules and politically sensitive populations limit how hard Centene can squeeze access.

The Playing Field

Centene is huge, but the peer set shows that scale alone is a weak defense when mix and medical-cost control lag. The best peers earn their premium through either better margin mix, service platforms, narrower operating discipline, or commercial/Blues franchises that do not depend as heavily on state Medicaid rate catch-up.

CNC's operating margin is shown excluding the $7.3B of 2025 impairment charges; reported GAAP operating margin was -3.9%. That adjustment is generous and still leaves Centene below every major peer, which is the competitive point: the company's Medicaid and Marketplace leadership gives it relevance, not automatic economics.

The moat is strongest in state relationships, local networks, claims data, and the ability to operate complex safety-net populations across many jurisdictions. It is weakest where investors often assume it is strongest: size. Size helps win and retain contracts, but a bad rate year on a high-acuity population overwhelms back-office scale.

Is This Business Cyclical?

Centene is cyclical, but the cycle is political and actuarial rather than economic. The cycle hits eligibility, member morbidity, reimbursement rates, risk adjustment, working capital, and Star-quality economics before it shows up in reported EPS.

The chart shows why this is not a normal defensive healthcare compounder. SG&A improved from 9.5% in 2020 to 7.4% in 2025, but HBR moved from 86.2% to 91.9%; medical-cost drift consumed the entire scale benefit.

The working-capital cycle matters too. Operating cash flow was only $154M in 2024, then $5.1B in 2025, and the 2025 year-end included a $4.0B stand-alone Part D risk-sharing receivable; a managed-care income statement can look stable while cash timing says risk has moved elsewhere.

The Metrics That Actually Matter

The stock will be explained by five operating measures, not by revenue growth or headline P/E. Each metric is a direct test of whether Centene can convert large regulated premium pools into recurring earnings.

Do not let the usual insurance ratios distract from the causal chain. Revenue growth can be bullish or bearish depending on which members Centene is adding, while a lower P/E can be a value signal or just the market discounting a structurally higher HBR.

What I’d Tell a Young Analyst

Start with rate adequacy, not the income statement. If Medicaid trend stabilizes, Marketplace repricing works with fewer but better members, and D-SNP/PDP overlap strengthens the Medicare franchise, Centene can recover without heroic top-line growth.

The market may be too quick to call Centene broken after 2025, but it is also right to demand proof. Watch Medicaid rate filings, paid Marketplace retention, behavioral-health utilization, Part D cash settlements, and Star-rating progress before giving management credit for normalized earnings.